Online Only Articles

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Karyopharm Therapeutics, Newton, MA
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Vol. 105 No. 5 (2020): May, 2020 https://doi.org/10.3324/haematol.2019.225375